Terence T. Sio

Dr. Terence T. Sio

Mayo Clinic Scottsdale-Phoenix, Arizona, Scottsdale, AZ, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
TSTerence T. Sio
Terence T. Sio
KCKenneth Chang
Kenneth Chang
RJRitujith Jayakrishnan
Ritujith Jayakrishnan
DWDifu Wu
Difu Wu
MPMary Politi
Mary Politi
MCMaureen Chung
Maureen Chung
Patients with breast cancer must choose among a variety of treatment options when first diagnosed. Patient age, independent of extent of disease, is also related to quality of life. This study examined the impact of patient age on treatment selected, factors influencing this selection, and perceived quality of life.

1 February 2016 in American Journal of Clinical Oncology
Verified
Journal Article
Open access
TSTerence T. Sio
Terence T. Sio
CVCharles C. Vu
Charles C. Vu
SSSchoeb Sohawon
Schoeb Sohawon
PHPaul Van Houtte
Paul Van Houtte
Juliette THARIATJuliette THARIAT
Juliette THARIAT
GBGil Bar-Sela
Gil Bar-Sela
To report characteristics, treatment, and outcomes for an international cohort of patients with extraskeletal osteosarcoma (ESOS). Through the Rare Cancer Network, retrospective data on patients with ESOS were collected. Patient characteristics, multimodality treatment information, and survival status were analyzed. Thirty-seven patients in 4 health care institutions were identified. Thirty-one (86%) patients had grade 3 or 4 tumors. Most patients (27 [73%]) had stage III disease. Fourteen (38%) received neoadjuvant chemotherapy or chemoradiation. Of 28 (85%) who underwent surgery, 21 (75%) had free margins achieved and 15 (41%) subsequently received adjuvant chemotherapy. At median follow-up of 45 months, 20 (55%) patients were alive, 13 (43%) of whom were disease free. Univariate analysis showed that poor overall survival was related to stage IV (P10 cm (P=0.002), and age (P=0.002). In multivariate analysis, primary size >10 cm (P=0.005) was prognostic for overall survival. For patients without metastases, univariate analysis showed disease-free survival (DFS) related to primary size >10 cm (P=0.003), surgery (P=0.004), local recurrence (P=0.003), and age (P10 cm (P=0.01) and older age (P<0.001) were significant for worse outcome. Multimodality treatment remains standard for localized ESOS, with indications for neoadjuvant therapy less clear. Larger tumor size and older age were prognostic of poorer DFS.

1 September 2022 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
ZZZhengfei Zhu
Zhengfei Zhu
JNJianjiao Ni
Jianjiao Ni
XCXuwei Cai
Xuwei Cai
SSShengfa Su
Shengfa Su
HZHongqing Zhuang
Hongqing Zhuang
XFXiaolong Fu
Xiaolong Fu
Consensus International consensus on radiotherapy in metastatic non-small cell lung cancer Zhengfei Zhu, Jianjiao Ni, Xuwei Cai, Shengfa Su, Hongqing Zhuang, Zhenzhou Yang, Ming Chen, Shenglin Ma, Conghua Xie, Yaping Xu, Jiancheng Li, Hong Ge, Anwen Liu, Lujun Zhao, Chuangzhou Rao, Congying Xie, Nan Bi, Zhouguang Hui, Guangying Zhu, Zhiyong Yuan, Jun Wang, Lina Zhao, Wei Zhou, Chai Hong Rim, Arturo Navarro-Martin, Ben G. L. Vanneste, Dirk De Ruysscher, J. Isabelle Choi, Jacek Jassem, Joe Y. Chang, Lucyna Kepka, Lukas Käsmann, Michael T. Milano, Paul Van Houtte, Rafal Suwinski, Alberto Traverso, Hiroshi Doi, Yang-Gun Suh, Georges Noël, Natsuo Tomita, Roman O. Kowalchuk, Terence T. Sio, Baosheng Li, Bing Lu, Xiaolong Fu

10 August 2022 in Clinical Lung Cancer
Verified
Journal Article
Open access
NYNathan Y. Yu
Nathan Y. Yu
TDTodd A. DeWees
Todd A. DeWees
MVMolly M. Voss
Molly M. Voss
WBWilliam G. Breen
William G. Breen
JCJennifer S. Chiang
Jennifer S. Chiang
TSTerence T. Sio
Terence T. Sio
Intensity-modulated proton therapy (IMPT) has the potential to reduce radiation dose to normal organs when compared to intensity-modulated radiation therapy (IMRT). We hypothesized that IMPT is associated with a reduced rate of cardiopulmonary toxicities in patients with Stage III NSCLC when compared with IMRT. We analyzed 163 consecutively treated patients with biopsy-proven, stage III NSCLC who received IMPT (n = 35, 21%) or IMRT (n = 128, 79%). Patient, tumor, and treatment characteristics were analyzed. Overall survival (OS), freedom-from distant metastasis (FFDM), freedom-from locoregional relapse (FFLR), and cardiopulmonary toxicities (CTCAE v5.0) were calculated using the Kaplan-Meier estimate. Univariate cox regressions were conducted for the final model. Median follow-up of surviving patients was 25.5 (range, 4.6-58.1) months. Median RT dose was 60 (range, 45-72) Gy [RBE]. OS, FFDM, and FFLR were not different based on RT modality. IMPT provided significant dosimetric pulmonary and cardiac sparing when compared to IMRT. IMPT was associated with a reduced rate of grade more than or equal to 3 pneumonitis (HR 0.25, P = .04) and grade more than or equal to 3 cardiac events (HR 0.33, P = .08). Pre-treatment predicted diffusing capacity for carbon monoxide less than equal to 57% (HR 2.8, P = .04) and forced expiratory volume in the first second less than equal to 61% (HR 3.1, P = .03) were associated with an increased rate of grade more than or equal to 3 pneumonitis. IMPT is associated with a reduced risk of clinically significant pneumonitis and cardiac events when compared with IMRT without compromising tumor control in stage III NSCLC. IMPT may provide a safer treatment option, particularly for high-risk patients with poor pretreatment pulmonary function.

6 January 2014 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
PDF file
TSTerence T. Sio
Terence T. Sio
SJSunyoung Jang
Sunyoung Jang
SLSung‐Woo Lee
Sung‐Woo Lee
BCBruce Curran
Bruce Curran
APAnil P. Pyakuryal
Anil P. Pyakuryal
ESEdward S. Sternick
Edward S. Sternick
The authors compared the relative dosimetric merits of Gamma Knife (GK) and CyberKnife (CK) in 15 patients with 26 brain metastases. All patients were initially treated with the Leksell GK 4C. The same patients were used to generate comparative CK treatment plans. The tissue volume receiving more than 12 Gy (V12), the difference between V12 and tumor volume (V12net), homogeneity index (HI), and gradient indices (GI25, GI50) were calculated. Peripheral dose falloff and three conformity indices were compared. The median tumor volume was 2.50 cm3 (range, 0. 044‐19.9). A median dose of 18 Gy (range, 15‐22) was prescribed. In GK and CK plans, doses were prescribed to the 40‐50% and 77‐92% isodose lines, respectively. Comparing GK to CK, the respective parametric values were: minimum dose ( vs. , ); mean dose ( vs., ); maximum dose ( vs., ); and HI ( vs. , ). The median dosimetric indices (GK vs. CK, with range) were: RTOG_CI, 1.76 (1.12‐4.14) vs. 1.53 (1.16‐2.12), ; CI, 1.76 (1.15‐4.14) vs. 1.55 (1.18‐2.21), ; nCI, 1.76 (1.59‐4.14) vs. 1.57 (1.20‐2.30), ; GI50, 2.91 (2.48‐3.67) vs. 4.90 (3.42‐11.68), ; GI25, 6.58 (4.18‐10.20) vs. 14.85 (8.80‐48.37), . Average volume ratio (AVR) differences favored GK at multiple normalized isodose levels . We concluded that in patients with brain metastases, CK and GK resulted in dosimetrically comparable plans that were nearly equivalent in several metrics, including target coverage and minimum dose within the target. Compared to GK, CK produced more homogenous plans with significantly lower mean and maximum doses, and achieved more conformal plans by RTOG_CI criteria. By GI and AVR analyses, GK plans had sharper peripheral dose falloff in most cases.PACS number: 89.20.‐a

1 September 2020 in Advances in Radiation Oncology
Verified
Journal Article
Open access
RBRonik S. Bhangoo
Ronik S. Bhangoo
TDTodd A. DeWees
Todd A. DeWees
NYNathan Y. Yu
Nathan Y. Yu
JDJulia X. Ding
Julia X. Ding
CLChenbin Liu
Chenbin Liu
TSTerence T. Sio
Terence T. Sio
Intensity modulated proton beam radiation therapy (IMPT) has a clinically significant dosimetric advantage over intensity modulated photon radiation therapy (IMRT) for the treatment of patients with esophageal cancer, particularly for sparing the heart and lungs. We compared acute radiation therapy–related toxicities and short-term clinical outcomes of patients with esophageal cancer who received treatment with IMPT or IMRT. We retrospectively reviewed the electronic health records of consecutive adult patients with esophageal cancer who underwent concurrent chemoradiotherapy with IMPT or IMRT in the definitive or neoadjuvant setting from January 1, 2014, through June 30, 2018, with additional follow-up data collected through January 31, 2019. Treatment-related toxicities were evaluated per the Common Terminology Criteria for Adverse Events, version 4. Survival outcomes were estimated with the Kaplan-Meier method. A total of 64 patients (32 per group) were included (median follow-up time: 10 months for IMPT patients vs 14 months for IMRT patients). The most common radiation therapy regimen was 45 Gy in 25 fractions, and 80% of patients received a simultaneous integrated boost to a median cumulative dose of 50 Gy. Similar numbers of IMPT patients (n = 15; 47%) and IMRT patients (n = 18; 56%) underwent surgery (P = .07), with no difference in pathologic complete response rates (IMPT: n = 5; 33% vs IMRT: n = 7; 39%; P = .14). At 1 year, the clinical outcomes also were similar for IMPT and IMRT patients, respectively. Local control was 92% versus 84% (P = .87), locoregional control 92% versus 80% (P = .76), distant metastasis–free survival 87% versus 65% (P = .08), progression-free survival 71% versus 45% (P = .15), and overall survival 74% versus 71% (P = .62). The rate of acute treatment–related grade 3 toxicity was similar between the groups (P = .71). In our early experience, IMPT is a safe and effective treatment when administered as part of definitive or trimodality therapy. Longer follow-up is required to evaluate the effectiveness of IMPT.